SCHEMBL13802473

SCHEMBL13802473

Nc1ccc(NCc2cccc(Cl)c2)c(C(=O)O)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 1/20 0.57
RPS6KB1 P23443 2/20 0.52
EGFR P00533 2/20 0.51
IGF1R P08069 2/20 0.51
AKT1 P31749 1/20 0.50
CD38 P28907 1/20 0.48
CISD1 Q9NZ45 1/20 0.48
MEN1 O00255 1/20 0.48
GAA P10253 1/20 0.48
MAPT P10636 1/20 0.48
KMT2A Q03164 1/20 0.48
APEX1 P27695 1/20 0.47
ACLY P53396 2/20 0.47
APP P05067 2/20 0.44
HDAC3 O15379 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
KDM4E B2RXH2 1/20 0.44
ASPH Q12797 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13802472 0.83 FFAR1 (0.48) MRGPRX4RPS6KB1CD38CISD1MEN1
SCHEMBL3808424 0.80 GAA (0.62) MRGPRX4CISD1MEN1GAAMAPT
SCHEMBL4217682 0.80 MAPT (0.77) EGFRIGF1RMEN1GAAMAPT
SCHEMBL2382952 0.78 MRGPRX4 (0.53) MRGPRX4RPS6KB1AKT1CD38CISD1
SCHEMBL15419642 0.76 HSD17B10 (0.55) MRGPRX4CISD1MEN1GAAMAPT
SCHEMBL1403529 0.74 APEX1 (0.50) MRGPRX4RPS6KB1EGFRAKT1GAA
SCHEMBL13802478 0.74 KDM4E (0.50) RPS6KB1MEN1GAAMAPTKMT2A
SCHEMBL28647503 0.73 GAA (0.58) MRGPRX4RPS6KB1AKT1CD38CISD1
SCHEMBL22469681 0.73 MRGPRX4 (1.00) MRGPRX4MEN1KMT2A
SCHEMBL31568452 0.73 MRGPRX4 (1.00) MRGPRX4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090155903-A1 PHARMACEUTICAL COMPOSITION AND METHOD MYRIAD GENETICS, INCORPORATED (US) 2009-06-18 US disclosed
US-20090155903-A1 PHARMACEUTICAL COMPOSITION AND METHOD MYRIAD GENETICS, INCORPORATED (US) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090155903-A1 PHARMACEUTICAL COMPOSITION AND METHOD APP, PSEN2, PSEN1 MRGPRX4 2781/4885RPS6KB1 4266/4885EGFR 3200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.